All In Biotech

Drug Trial Radar · NCT03846219

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)

Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Actual

Start

Jan 28, 2019

Primary completion

Apr 24, 2020

Study completion Dec 2029

Sponsor

Lead sponsor
Immunic AGIndustry
Sponsor type
Industry
First posted
Feb 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), 30 mg/day and 45 mg/day in the main study, cohort 1 (and 10 mg/day for the patients in the cohort 2 substudy), in patients with RRMS and evidence of active disease. The trial consists of a screening period, a blinded 24-week main treatment period, and an optional initially blinded, then open-label extended treatment period of up to 9.5 years. About 40 centers are planned to participate in Romania, Bulgaria, Ukraine, and Poland; potential additional centers in Hungary and Croatia were not used. The study started with 195 patients in the main group (cohort 1) planned to be randomized 1:1:1 to treatment with 30 mg/day or 45 mg/day IMU-838, or placebo (65 patients each) in the main treatment period. During the extended treatment period, patients were initially re-randomized so that patients previously on placebo were re-randomized 1:1 to treatment with 30 g/day or 45 mg/day IMU-838, all other patients were re-randomized to the same treatment they previously received. With approval of Protocol Version 3.0, a sub-study patient group (cohort 2) has been added with up to 60 patients, randomized to placebo or 10 mg IMU-838 for 24 weeks after which the option is available to continue into the extended treatment period and the recommended dose of 30 mg/day. However, based on discussion between investigator and patient 45 mg/day IMU-838/day may also be used.

Conditions

  • Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions

  • IMU-838 (30 mg/day)Drug

    * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily.

  • IMU-838 (45 mg/day)Drug

    * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily.

  • PlaceboDrug

    * Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards. * Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.

  • IMU-838 (10 mg/day)Drug

    * Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily). * Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI LesionsTime frame: Up to Week 24

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • MHAT Pulse AD, Department of Neurology Diseases

    Blagoevgrad, Bulgaria

  • UMHAT "Dr.Georgi Stranski" EAD Pleven Department of Professional Diseases

    Pleven, Bulgaria

  • MHAT "Heart and brain" EAD Pleven Department of Neurology Diseases

    Pleven, Bulgaria

  • UMHAT " Kaspela" EOOD, Department of Neurology Diseases

    Plovdiv, Bulgaria

  • UMHAT "Kanev Ruse", Department of General and Vascular Neurology

    Rousse, Bulgaria

  • MHATNP "Sveti Naum" EAD, Neurology Clinic for Movement Disorders, First Department of Neurology Diseases

    Sofia, Bulgaria

  • MHATNPsy "Sveti Naum" EAD, Intensive Therapy Clinic Of Neurology Diseases

    Sofia, Bulgaria

  • DCC "Neoclinic" EAD, Cabinet Neurology Diseases

    Sofia, Bulgaria

  • UMHAT "Alexandrovska" EAD, Clinic of Neurology Diseases, Department of Inherited Degenerative and Immunoinflamatori Diseases at Peripheral Nervous System

    Sofia, Bulgaria

  • UMHAT "Sveti Ivan Rilski" EAD Sofia Clinic of Neurological Diseases

    Sofia, Bulgaria

  • UMHAT"Alexandrovska"EAD, Department of Degenerative and Immunoinflamatory Disease of the Central Nervous System

    Sofia, Bulgaria

  • Central Clinical Base-Medical Institute - Ministry of Interior, Neurology Clinic

    Sofia, Bulgaria

  • Military Medical Academy - Sofia, Clinic of Neurology Diseases

    Sofia, Bulgaria

  • Military Medical Academy, Clinic of Functional Diagnostics of Nevous System

    Sofia, Bulgaria

  • UMHAT " Sveta Marina EAD, First Neurology Clinic

    Varna, Bulgaria

  • Nasz Lekarz Ośrodek Badań Klinicznych

    Bydgoszcz, Poland

  • Specjalistyczna Praktyka Lekarska Paweł Bochniak

    Bydgoszcz, Poland

  • Indywidualna Praktyka Lekarska Prof. Konrad Rejdak

    Lublin, Poland

  • BioResearch Group Sp. Z o.o

    Nadarzyn, Poland

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • S.C. Sana Monitoring Srl

    Bucharest, Romania

  • Spitalul Universitar Elias Bucharesti

    Bucharest, Romania

  • S.C. Quantum Medical Center Srl

    Bucharest, Romania

  • Spitalul Clinic Colentina Bucharest, Neurologie 2

    Bucharest, Romania

  • Spitalul Clinic Cai Ferate Constanta

    Constanța, Romania

  • Chernihiv Regional Hospital, Department of Neurology

    Chernihiv, Ukraine

  • Dnipropetrovsk Municipal Hospital #5, Neurological Department of the inflammatory and demyelinating diseases of CNS

    Dnipro, Ukraine

  • Ukrainian State Research Institute of Medical and Social Problems of Disability of MOH of Ukraine

    Dnipro, Ukraine

  • Regional Clinical Hospital, Department of vascular Neurology

    Ivano-Frankivsk, Ukraine

  • Kharkiv Regional Clinical Hospital, Department of Neurology

    Kharkiv, Ukraine

  • Institute of Neurology, Psychiatry and Narcology NAMSU

    Kharkiv, Ukraine

  • Kyiv City Clinical Hospital #4, Department of Neurology

    Kyiv, Ukraine

  • Volyn Regional Clinical Hospital, Department of Neurology

    Lutsk, Ukraine

  • Poltava Regional Clinical Hospital n.a. Sklifosovskyi, Department of Neurology

    Poltava, Ukraine

  • Regional Clinical Centre of Neurosurgery and Neurology, Department #2

    Uzhhorod, Ukraine

  • Vinnytsya Regional Psychoneurology Hospital n.a. Yushchenko, Department of Neurology #3

    Vinnytsia, Ukraine

  • City Clinical Hospital #2, Department of Neurology

    Zaporizhzhya, Ukraine

  • Zaporizhzhya Regional Clinical Hospital, Department of Neurology #1

    Zaporizhzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.